VASO VASO Corp
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 839087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.2%
TTM net income YoY-5.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR-40.6%
Margins
Gross margin68.2%
Operating margin-3.7%
Net margin3.6%
FCF margin—
EBITDA margin-2.3%
Returns
ROE8.3%
ROA2.9%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio2.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.77x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $89.10M | $86.77M | $81.02M | $79.29M | $75.58M |
| Cost of revenue | $34.42M | $34.72M | $30.43M | $31.39M | $32.45M |
| Gross profit | $54.67M | $52.05M | $50.59M | $47.90M | $43.13M |
| R&D expense | $728,000 | $851,000 | $755,000 | $605,000 | $1.72M |
| SG&A expense | $52.20M | $48.98M | $45.08M | $40.84M | $38.59M |
| Operating income | -$2.89M | $285,000 | $4.20M | $6.45M | $2.82M |
| Interest expense | $25,000 | $4,000 | $50,000 | $44,000 | $312,000 |
| Pretax income | -$1.31M | $1.28M | $4.91M | $6.55M | $6.25M |
| Income tax | -$2.88M | $326,000 | $100,000 | -$4.74M | $151,000 |
| Net income | $1.57M | $951,000 | $4.80M | $11.29M | $6.10M |
| EBITDA | -$2.03M | $1.11M | $5.19M | $8.38M | $6.66M |
| EPS (basic) | 0.01 | 0.01 | 0.03 | 0.07 | 0.04 |
| EPS (diluted) | 0.01 | 0.01 | 0.03 | 0.06 | — |
| Weighted avg. shares (diluted) | 176.00M | 175.59M | 175.54M | 174.66M | 173.77M |
| Balance sheet | |||||
| Cash & equivalents | $34.08M | $26.27M | $11.34M | $11.82M | $6.03M |
| Short-term investments | — | — | $13.98M | $8.50M | $629,000 |
| Receivables | — | $916,000 | $901,000 | $21.46M | $21.20M |
| Inventory | $833,000 | $911,000 | $1.47M | $1.47M | $1.15M |
| Current assets | $58.56M | $51.19M | $45.10M | $40.99M | $27.80M |
| PP&E, net | $121,000 | $1.54M | $1.17M | $1.34M | $2.17M |
| Goodwill | $1.23M | $1.18M | $15.59M | $15.61M | $15.72M |
| Intangibles | $1.25M | $1.61M | $1.41M | $1.51M | $2.04M |
| Total assets | $89.32M | $82.94M | $75.76M | $71.64M | $52.36M |
| Current liabilities | $36.85M | $34.72M | $30.04M | $31.51M | $31.00M |
| Short-term debt | — | — | — | $9,000 | $8,000 |
| Long-term debt | — | — | — | $15,000 | $23,000 |
| Total debt | — | — | — | $24,000 | $31,000 |
| Total liabilities | $59.89M | $55.24M | $48.91M | $49.58M | $41.05M |
| Shareholders' equity | $29.43M | $27.70M | $26.84M | $22.07M | $11.08M |
| Net debt | — | — | — | -$11.80M | -$5.99M |
| Shares outstanding | 175.95M | 175.70M | 175.32M | 175.13M | 175.13M |
| Cash flow statement | |||||
| Operating cash flow | $9.27M | $3.28M | $5.30M | $14.42M | $7.82M |
| Capital expenditure | — | — | — | $566,000 | $415,000 |
| Free cash flow | — | — | — | $13.85M | $7.40M |
| Investing cash flow | -$725,000 | $11.73M | -$5.66M | -$8.42M | -$260,000 |
| Financing cash flow | $248,000 | -$89,000 | -$134,000 | -$230,000 | -$8.33M |
| Depreciation & amortization | $858,000 | $824,000 | $999,000 | $1.92M | $3.84M |
| Stock-based compensation | $33,000 | $54,000 | $48,000 | $35,000 | $31,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.